ARCHIVES

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

This article is from The Cancer Letter archive.

Vol. 07 No. 21 | May 22, 1981

Download PDF Visit The Full Archive

Related Articles

In Brief: Breast Cancer Coalition Seeks Survivors, Activists For 3-Day Course In Advocacy

April 28, 1995

NCAB Ok’s Funding First Three Years Of Diet Trial

December 7, 1990

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

December 19, 2014

ORI Finds Misconduct By Harvard Physician On Cancer Protocol; Two Other Cases

June 9, 1995

DCT Programs Status Reported to Board

July 5, 1985

NCI Backed Studies Indicate Overweight Not Much Of a Cancer Risk Factor

June 19, 1987